Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Statesville, NC
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Statesville, NC
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Portland, OR
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Seattle, WA
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Mission Hills, CA
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Hialeah, FL
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Neptune, NJ
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Neptune, NJ
Click here to add this to my saved trials
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Dallas, TX
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Houston, TX
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Houston, TX
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Alexandria, VA
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Alexandria, VA
Click here to add this to my saved trials
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Norfolk, VA
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV
HBV Prevention for Homeless at Risk for HBV/HCV/HIV
Status: Enrolling
Updated:  4/5/2013
Friends Community Center
mi
from
Los Angeles, CA
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV
HBV Prevention for Homeless at Risk for HBV/HCV/HIV
Status: Enrolling
Updated: 4/5/2013
Friends Community Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Coronado, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Coronado, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Newport Beach, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Riverside, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
San Francisco, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
San Francisco, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
DeLand, FL
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
West Palm Beach, FL
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Minneapolis, MN
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Egg Harbor Township, NJ
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Hillsborough, NJ
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Manhasset, NY
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Wilmington, NC
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Providence, RI
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Germantown, TN
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Murray, UT
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Fairfax, VA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated:  4/13/2013
Clinical Research Facility
mi
from
Milwaukee, WI
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) INfection (PEARL-IV)
Status: Enrolling
Updated: 4/13/2013
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection
Status: Enrolling
Updated:  4/16/2013
Mount Sinai School of Medicine
mi
from
New York, NY
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection
Status: Enrolling
Updated: 4/16/2013
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers
Status: Enrolling
Updated:  5/2/2013
Clinical Pharmacology of Miami, Inc.
mi
from
Hialeah, FL
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers
Status: Enrolling
Updated: 5/2/2013
Clinical Pharmacology of Miami, Inc.
mi
from
Hialeah, FL
Click here to add this to my saved trials
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers
Status: Enrolling
Updated:  5/2/2013
Orlando Clinical Research Center
mi
from
Orlando, FL
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers
Status: Enrolling
Updated: 5/2/2013
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers
Status: Enrolling
Updated:  5/2/2013
American Research Corporation (ARC)
mi
from
San Antonio, TX
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers
Status: Enrolling
Updated: 5/2/2013
American Research Corporation (ARC)
mi
from
San Antonio, TX
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Louisville, KY
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
New Orleans, LA
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
St. Louis, MO
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
New York, NY
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Cleveland, OH
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Tulsa, OK
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Carnegie, PA
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Carnegie, PA
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Dallas, TX
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Houston, TX
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Norfolk, VA
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials